H.C. Wainwright lowered the firm’s price target on KalVista to $20 from $24 and keeps a Buy rating on the shares. The analyst believes sebetralstat is well positioned for approval and is backed by the positive Phase 3 KONFIDENT trial data.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KALV: